메뉴 건너뛰기




Volumn 239, Issue 1, 2015, Pages 192-202

A concise review of non-alcoholic fatty liver disease

Author keywords

Cardiovascular disease; Dyslipidaemia; Insulin resistance; Non alcoholic fatty liver disease; Pathogenesis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; BETAINE; CYTOPROTECTIVE AGENT; FATTY ACID; INSULIN SENSITIZING AGENT; METFORMIN; PENTOXIFYLLINE; URSODEOXYCHOLIC ACID; TRIACYLGLYCEROL;

EID: 84922622191     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.001     Document Type: Review
Times cited : (242)

References (139)
  • 1
    • 84861543083 scopus 로고    scopus 로고
    • The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    • Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
    • (2012) Hepatology , vol.55 , Issue.6 , pp. 2005-2023
    • Chalasani, N.1
  • 2
    • 77950323927 scopus 로고    scopus 로고
    • Pathogenesis of non-alcoholic fatty liver disease
    • Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. Qjm 2010, 103(2):71-83.
    • (2010) Qjm , vol.103 , Issue.2 , pp. 71-83
    • Dowman, J.K.1    Tomlinson, J.W.2    Newsome, P.N.3
  • 3
    • 75449102165 scopus 로고    scopus 로고
    • Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?
    • Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010, 51(2):373-375.
    • (2010) Hepatology , vol.51 , Issue.2 , pp. 373-375
    • Angulo, P.1
  • 4
    • 84888439070 scopus 로고    scopus 로고
    • Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease
    • Chang E., Park C.Y., Park S.W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J.Diabetes Investig. 2013, 4(6):517-524.
    • (2013) J.Diabetes Investig. , vol.4 , Issue.6 , pp. 517-524
    • Chang, E.1    Park, C.Y.2    Park, S.W.3
  • 5
    • 84872765906 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?
    • Ahmed M.H., Barakat S., Almobarak A.O. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?. J.Obes. 2012, 2012:483135.
    • (2012) J.Obes. , vol.2012 , pp. 483135
    • Ahmed, M.H.1    Barakat, S.2    Almobarak, A.O.3
  • 6
    • 84881478224 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease and cardiovascular risk
    • Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol. 2013, 167(4):1109-1117.
    • (2013) Int. J. Cardiol. , vol.167 , Issue.4 , pp. 1109-1117
    • Brea, A.1    Puzo, J.2
  • 7
    • 53549112749 scopus 로고    scopus 로고
    • Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
    • Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
    • (2008) Diabetologia , vol.51 , Issue.11 , pp. 1947-1953
    • Targher, G.1    Marra, F.2    Marchesini, G.3
  • 8
    • 84896690517 scopus 로고    scopus 로고
    • Extrahepatic complications of nonalcoholic fatty liver disease
    • Armstrong M.J., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59(3):1174-1197.
    • (2014) Hepatology , vol.59 , Issue.3 , pp. 1174-1197
    • Armstrong, M.J.1
  • 9
    • 79960029926 scopus 로고    scopus 로고
    • Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
    • Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34(3):274-285.
    • (2011) Aliment. Pharmacol. Ther. , vol.34 , Issue.3 , pp. 274-285
    • Vernon, G.1    Baranova, A.2    Younossi, Z.M.3
  • 10
    • 0025260531 scopus 로고
    • Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors
    • Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
    • (1990) Hepatology , vol.12 , Issue.5 , pp. 1106-1110
    • Wanless, I.R.1    Lentz, J.S.2
  • 11
    • 79956062113 scopus 로고    scopus 로고
    • Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study
    • Williamson R.M., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care 2011, 34(5):1139-1144.
    • (2011) Diabetes Care , vol.34 , Issue.5 , pp. 1139-1144
    • Williamson, R.M.1
  • 12
    • 33748110788 scopus 로고    scopus 로고
    • Hepatic histology in obese patients undergoing bariatric surgery
    • Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J.Hepatol. 2006, 45(4):600-606.
    • (2006) J.Hepatol. , vol.45 , Issue.4 , pp. 600-606
    • Machado, M.1    Marques-Vidal, P.2    Cortez-Pinto, H.3
  • 13
    • 84877854022 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease
    • Gaggini M., et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5(5):1544-1560.
    • (2013) Nutrients , vol.5 , Issue.5 , pp. 1544-1560
    • Gaggini, M.1
  • 14
    • 84876522373 scopus 로고    scopus 로고
    • Current concepts and management approaches in nonalcoholic fatty liver disease
    • Attar B.M., Van Thiel D.H. Current concepts and management approaches in nonalcoholic fatty liver disease. Sci. World J. 2013, 2013:481893.
    • (2013) Sci. World J. , vol.2013 , pp. 481893
    • Attar, B.M.1    Van Thiel, D.H.2
  • 15
    • 10644220306 scopus 로고    scopus 로고
    • Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
    • Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
    • (2004) Hepatology , vol.40 , Issue.6 , pp. 1387-1395
    • Browning, J.D.1
  • 16
    • 84857429228 scopus 로고    scopus 로고
    • Ethnicity and nonalcoholic fatty liver disease
    • Bambha K., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55(3):769-780.
    • (2012) Hepatology , vol.55 , Issue.3 , pp. 769-780
    • Bambha, K.1
  • 17
    • 33750606061 scopus 로고    scopus 로고
    • Long-term follow-up of patients with NAFLD and elevated liver enzymes
    • Ekstedt M., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
    • (2006) Hepatology , vol.44 , Issue.4 , pp. 865-873
    • Ekstedt, M.1
  • 18
    • 67649306197 scopus 로고    scopus 로고
    • Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
    • Argo C.K., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J.Hepatol. 2009, 51(2):371-379. http://www.ncbi.nlm.nih.gov/pubmed/?term=Northup%20PG%5BAuthor%5D%26cauthor=true%26cauthor_uid=19501928.
    • (2009) J.Hepatol. , vol.51 , Issue.2 , pp. 371-379
    • Argo, C.K.1    Al-Osaimi, A.M.2    Caldwell, S.H.3
  • 19
    • 84907969087 scopus 로고    scopus 로고
    • Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
    • Perazzo H., et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment. Pharmacol. Ther. 2014, 40(9):1081-1093.
    • (2014) Aliment. Pharmacol. Ther. , vol.40 , Issue.9 , pp. 1081-1093
    • Perazzo, H.1
  • 20
    • 79960215555 scopus 로고    scopus 로고
    • Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period
    • Hamabe A., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J.Gastroenterol. 2011, 46(6):769-778.
    • (2011) J.Gastroenterol. , vol.46 , Issue.6 , pp. 769-778
    • Hamabe, A.1
  • 21
    • 46249090385 scopus 로고    scopus 로고
    • Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease
    • Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47(6):1947-1954.
    • (2008) Hepatology , vol.47 , Issue.6 , pp. 1947-1954
    • Dunn, W.1    Xu, R.2    Schwimmer, J.B.3
  • 22
    • 84896879418 scopus 로고    scopus 로고
    • Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease
    • Stanković M.N., et al. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch. Med. Res. 2014, 45(2):116-124.
    • (2014) Arch. Med. Res. , vol.45 , Issue.2 , pp. 116-124
    • Stanković, M.N.1
  • 23
    • 67651173053 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers
    • Edens M.A., Kuipers F., Stolk R.P. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes. Rev. 2009, 10(4):412-419.
    • (2009) Obes. Rev. , vol.10 , Issue.4 , pp. 412-419
    • Edens, M.A.1    Kuipers, F.2    Stolk, R.P.3
  • 24
    • 77957375969 scopus 로고    scopus 로고
    • Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
    • Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N.Engl. J. Med. 2010, 363(14):1341-1350.
    • (2010) N.Engl. J. Med. , vol.363 , Issue.14 , pp. 1341-1350
    • Targher, G.1    Day, C.P.2    Bonora, E.3
  • 25
    • 79151478841 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease and the coronary artery disease
    • Treeprasertsuk S., Lopez-Jimenez F., Lindor K.D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig. Dis. Sci. 2011, 56(1):35-45.
    • (2011) Dig. Dis. Sci. , vol.56 , Issue.1 , pp. 35-45
    • Treeprasertsuk, S.1    Lopez-Jimenez, F.2    Lindor, K.D.3
  • 26
    • 0031947715 scopus 로고    scopus 로고
    • Steatohepatitis: a tale of two "hits"?
    • Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
    • (1998) Gastroenterology , vol.114 , Issue.4 , pp. 842-845
    • Day, C.P.1    James, O.F.2
  • 27
    • 0037153158 scopus 로고    scopus 로고
    • Acentral role for JNK in obesity and insulin resistance
    • Hirosumi J., et al. Acentral role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
    • (2002) Nature , vol.420 , Issue.6913 , pp. 333-336
    • Hirosumi, J.1
  • 28
    • 14644427890 scopus 로고    scopus 로고
    • Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB
    • Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11(2):183-190.
    • (2005) Nat. Med. , vol.11 , Issue.2 , pp. 183-190
    • Cai, D.1
  • 29
    • 84867692901 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences
    • Del Ben M., et al. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg. Med. 2012, 7(Suppl.3):S291-S296.
    • (2012) Intern Emerg. Med. , vol.7 , Issue.SUPPL.3 , pp. S291-S296
    • Del Ben, M.1
  • 30
    • 0033231294 scopus 로고    scopus 로고
    • Association of nonalcoholic fatty liver disease with insulin resistance
    • Marchesini G., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107(5):450-455.
    • (1999) Am. J. Med. , vol.107 , Issue.5 , pp. 450-455
    • Marchesini, G.1
  • 31
    • 38649110496 scopus 로고    scopus 로고
    • Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
    • Biddinger S.B., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell. Metab. 2008, 7(2):125-134.
    • (2008) Cell. Metab. , vol.7 , Issue.2 , pp. 125-134
    • Biddinger, S.B.1
  • 32
    • 38649116056 scopus 로고    scopus 로고
    • Selective versus total insulin resistance: a pathogenic paradox
    • Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell. Metab. 2008, 7(2):95-96.
    • (2008) Cell. Metab. , vol.7 , Issue.2 , pp. 95-96
    • Brown, M.S.1    Goldstein, J.L.2
  • 33
    • 77953766314 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease proteomics
    • Rodriguez-Suarez E., et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin. Appl. 2010, 4(4):362-371.
    • (2010) Proteomics Clin. Appl. , vol.4 , Issue.4 , pp. 362-371
    • Rodriguez-Suarez, E.1
  • 34
    • 84904395679 scopus 로고    scopus 로고
    • Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis
    • Lim J.W., Dillon J., Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis. World J. Gastroenterol. 2014, 20(26):8325-8340.
    • (2014) World J. Gastroenterol. , vol.20 , Issue.26 , pp. 8325-8340
    • Lim, J.W.1    Dillon, J.2    Miller, M.3
  • 35
    • 77957302090 scopus 로고    scopus 로고
    • Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
    • Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl.2):83-92.
    • (2010) Diabetes Obes. Metab. , vol.12 , Issue.SUPPL.2 , pp. 83-92
    • Ferre, P.1    Foufelle, F.2
  • 36
    • 84874600898 scopus 로고    scopus 로고
    • De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health
    • Eissing L., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat. Commun. 2013, 4:1528.
    • (2013) Nat. Commun. , vol.4 , pp. 1528
    • Eissing, L.1
  • 37
    • 79955121832 scopus 로고    scopus 로고
    • Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes
    • Wu M., et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(13):5378-5383.
    • (2011) Proc. Natl. Acad. Sci. U. S. A. , vol.108 , Issue.13 , pp. 5378-5383
    • Wu, M.1
  • 38
    • 84907386500 scopus 로고    scopus 로고
    • Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease
    • Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N.Engl. J. Med. 2014, 371(12):1131-1141.
    • (2014) N.Engl. J. Med. , vol.371 , Issue.12 , pp. 1131-1141
    • Shulman, G.I.1
  • 39
    • 46449131992 scopus 로고    scopus 로고
    • Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
    • Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin. Sci. Lond. 2008, 115(1):1-12.
    • (2008) Clin. Sci. Lond. , vol.115 , Issue.1 , pp. 1-12
    • Loria, P.1    Lonardo, A.2    Targher, G.3
  • 40
    • 0038509036 scopus 로고    scopus 로고
    • Lipotoxicity: when tissues overeat
    • Schaffer J.E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 2003, 14(3):281-287.
    • (2003) Curr. Opin. Lipidol. , vol.14 , Issue.3 , pp. 281-287
    • Schaffer, J.E.1
  • 41
    • 0035912744 scopus 로고    scopus 로고
    • Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance
    • Kim J.K., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(13):7522-7527.
    • (2001) Proc. Natl. Acad. Sci. U. S. A. , vol.98 , Issue.13 , pp. 7522-7527
    • Kim, J.K.1
  • 42
    • 0035032163 scopus 로고    scopus 로고
    • Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance
    • Ferreira L.D., et al. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 2001, 50(5):1064-1068.
    • (2001) Diabetes , vol.50 , Issue.5 , pp. 1064-1068
    • Ferreira, L.D.1
  • 43
    • 0022552278 scopus 로고
    • Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver
    • Bouwens L., et al. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 1986, 6(4):718-722.
    • (1986) Hepatology , vol.6 , Issue.4 , pp. 718-722
    • Bouwens, L.1
  • 44
    • 0026721306 scopus 로고
    • Evidence for Kupffer cell migration along liver sinusoids, from high-resolution invivo microscopy
    • MacPhee P.J., Schmidt E.E., Groom A.C. Evidence for Kupffer cell migration along liver sinusoids, from high-resolution invivo microscopy. Am. J. Physiol. 1992, 263(1 Pt 1):G17-G23.
    • (1992) Am. J. Physiol. , vol.263 , Issue.1 , pp. G17-G23
    • MacPhee, P.J.1    Schmidt, E.E.2    Groom, A.C.3
  • 45
    • 34548272744 scopus 로고    scopus 로고
    • Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis
    • Rivera C.A., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J.Hepatol. 2007, 47(4):571-579.
    • (2007) J.Hepatol. , vol.47 , Issue.4 , pp. 571-579
    • Rivera, C.A.1
  • 46
    • 75449101395 scopus 로고    scopus 로고
    • Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity
    • Stienstra R., et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51(2):511-522.
    • (2010) Hepatology , vol.51 , Issue.2 , pp. 511-522
    • Stienstra, R.1
  • 47
    • 67349205002 scopus 로고    scopus 로고
    • Kupffer cells in non-alcoholic fatty liver disease: the emerging view
    • Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J.Hepatol. 2009, 51(1):212-223.
    • (2009) J.Hepatol. , vol.51 , Issue.1 , pp. 212-223
    • Baffy, G.1
  • 48
    • 33947261669 scopus 로고    scopus 로고
    • Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients
    • Park J.W., et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J.Gastroenterol. Hepatol. 2007, 22(4):491-497.
    • (2007) J.Gastroenterol. Hepatol. , vol.22 , Issue.4 , pp. 491-497
    • Park, J.W.1
  • 49
    • 0033789518 scopus 로고    scopus 로고
    • Adipose tissue as an endocrine organ
    • Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11(8):327-332.
    • (2000) Trends Endocrinol. Metab. , vol.11 , Issue.8 , pp. 327-332
    • Ahima, R.S.1    Flier, J.S.2
  • 50
    • 0042165989 scopus 로고    scopus 로고
    • Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
    • Feldstein A.E., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
    • (2003) Gastroenterology , vol.125 , Issue.2 , pp. 437-443
    • Feldstein, A.E.1
  • 51
    • 0348134733 scopus 로고    scopus 로고
    • Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
    • Feldstein A.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J.Hepatol. 2003, 39(6):978-983.
    • (2003) J.Hepatol. , vol.39 , Issue.6 , pp. 978-983
    • Feldstein, A.E.1
  • 52
    • 42949086433 scopus 로고    scopus 로고
    • Cellular and molecular mechanisms of liver injury
    • Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134(6):1641-1654.
    • (2008) Gastroenterology , vol.134 , Issue.6 , pp. 1641-1654
    • Malhi, H.1    Gores, G.J.2
  • 53
    • 84887553152 scopus 로고    scopus 로고
    • PNPLA3 I148M polymorphism and progressive liver disease
    • Dongiovanni P., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J. Gastroenterol. 2013, 19(41):6969-6978.
    • (2013) World J. Gastroenterol. , vol.19 , Issue.41 , pp. 6969-6978
    • Dongiovanni, P.1
  • 54
    • 79953745343 scopus 로고    scopus 로고
    • Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits
    • Speliotes E.K., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7(3):e1001324.
    • (2011) PLoS Genet. , vol.7 , Issue.3 , pp. e1001324
    • Speliotes, E.K.1
  • 55
    • 56749096610 scopus 로고    scopus 로고
    • Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
    • Romeo S., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40(12):1461-1465.
    • (2008) Nat. Genet. , vol.40 , Issue.12 , pp. 1461-1465
    • Romeo, S.1
  • 56
    • 67349174005 scopus 로고    scopus 로고
    • Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans
    • Kotronen A., et al. Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52(6):1056-1060.
    • (2009) Diabetologia , vol.52 , Issue.6 , pp. 1056-1060
    • Kotronen, A.1
  • 57
    • 79957462315 scopus 로고    scopus 로고
    • Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
    • Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53(6):1883-1894.
    • (2011) Hepatology , vol.53 , Issue.6 , pp. 1883-1894
    • Sookoian, S.1    Pirola, C.J.2
  • 58
    • 78049457761 scopus 로고    scopus 로고
    • Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease
    • 1576.e1-6
    • Chalasani N., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139(5):1567-1576. 1576.e1-6.
    • (2010) Gastroenterology , vol.139 , Issue.5 , pp. 1567-1576
    • Chalasani, N.1
  • 59
    • 84857398069 scopus 로고    scopus 로고
    • Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents
    • Santoro N., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012, 55(3):781-789.
    • (2012) Hepatology , vol.55 , Issue.3 , pp. 781-789
    • Santoro, N.1
  • 60
    • 84874171496 scopus 로고    scopus 로고
    • Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects
    • Fu D., et al. Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. PLoS One 2013, 8(2):e55727.
    • (2013) PLoS One , vol.8 , Issue.2 , pp. e55727
    • Fu, D.1
  • 61
    • 84919385811 scopus 로고    scopus 로고
    • The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease
    • Ferolla S.M., et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014, 6(12):5583-5599.
    • (2014) Nutrients , vol.6 , Issue.12 , pp. 5583-5599
    • Ferolla, S.M.1
  • 62
    • 84888023932 scopus 로고    scopus 로고
    • Obesity and NAFLD: the role of bacteria and microbiota
    • Duseja A., Chawla Y.K. Obesity and NAFLD: the role of bacteria and microbiota. Clin. Liver Dis. 2014, 18(1):59-71.
    • (2014) Clin. Liver Dis. , vol.18 , Issue.1 , pp. 59-71
    • Duseja, A.1    Chawla, Y.K.2
  • 63
    • 84916218639 scopus 로고    scopus 로고
    • Probiotics and nonalcoholic fatty liver disease
    • Eslamparast T., et al. Probiotics and nonalcoholic fatty liver disease. Middle East J. Dig. Dis. 2013, 5(3):129-136.
    • (2013) Middle East J. Dig. Dis. , vol.5 , Issue.3 , pp. 129-136
    • Eslamparast, T.1
  • 64
    • 0029874138 scopus 로고    scopus 로고
    • The NF-kappa B and I kappa B proteins: new discoveries and insights
    • Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev. Immunol. 1996, 14:649-683.
    • (1996) Annu Rev. Immunol. , vol.14 , pp. 649-683
    • Baldwin, A.S.1
  • 65
    • 84856957894 scopus 로고    scopus 로고
    • Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
    • Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
    • (2012) Nature , vol.482 , Issue.7384 , pp. 179-185
    • Henao-Mejia, J.1
  • 66
    • 84879604697 scopus 로고    scopus 로고
    • Intestinal microbiota in patients with nonalcoholic fatty liver disease
    • Mouzaki M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58(1):120-127.
    • (2013) Hepatology , vol.58 , Issue.1 , pp. 120-127
    • Mouzaki, M.1
  • 67
    • 84922614287 scopus 로고    scopus 로고
    • Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
    • Jiang C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J.Clin. Invest 2014.
    • (2014) J.Clin. Invest
    • Jiang, C.1
  • 68
    • 84894234723 scopus 로고    scopus 로고
    • Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
    • Ballestri S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(7):1724-1745.
    • (2014) World J. Gastroenterol. , vol.20 , Issue.7 , pp. 1724-1745
    • Ballestri, S.1
  • 69
    • 80051552944 scopus 로고    scopus 로고
    • Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation
    • Ndumele C.E., et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31(8):1927-1932.
    • (2011) Arterioscler. Thromb. Vasc. Biol. , vol.31 , Issue.8 , pp. 1927-1932
    • Ndumele, C.E.1
  • 70
    • 84894286316 scopus 로고    scopus 로고
    • Prothrombotic factors in histologically proven NAFLD and NASH
    • Verrijken A., et al. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology 2013, 59:121-129.
    • (2013) Hepatology , vol.59 , pp. 121-129
    • Verrijken, A.1
  • 71
    • 34547596738 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
    • Yoneda M., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J.Gastroenterol. 2007, 42(7):573-582.
    • (2007) J.Gastroenterol. , vol.42 , Issue.7 , pp. 573-582
    • Yoneda, M.1
  • 72
    • 84922640340 scopus 로고    scopus 로고
    • High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and Stenosis Burden: results from the ROMICAT II trial
    • Puchner S.B., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and Stenosis Burden: results from the ROMICAT II trial. Radiology 2014, 140933.
    • (2014) Radiology , pp. 140933
    • Puchner, S.B.1
  • 73
    • 84928209634 scopus 로고    scopus 로고
    • Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
    • (Epub ahead of print)
    • Ekstedt M., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27368.
    • (2014) Hepatology
    • Ekstedt, M.1
  • 74
    • 84921487729 scopus 로고    scopus 로고
    • TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
    • (Epub ahead of print)
    • Dongiovanni P., et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27490.
    • (2014) Hepatology
    • Dongiovanni, P.1
  • 75
    • 33746421488 scopus 로고    scopus 로고
    • Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease
    • Targher G., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29(6):1325-1330.
    • (2006) Diabetes Care , vol.29 , Issue.6 , pp. 1325-1330
    • Targher, G.1
  • 76
    • 84872339818 scopus 로고    scopus 로고
    • Assessment of endothelial function in patients with nonalcoholic fatty liver disease
    • Colak Y., et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013, 43(1):100-107.
    • (2013) Endocrine , vol.43 , Issue.1 , pp. 100-107
    • Colak, Y.1
  • 77
    • 77954423206 scopus 로고    scopus 로고
    • Association between nonalcoholic fatty liver disease and coronary artery calcification
    • Chen C.H., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig. Dis. Sci. 2010, 55(6):1752-1760.
    • (2010) Dig. Dis. Sci. , vol.55 , Issue.6 , pp. 1752-1760
    • Chen, C.H.1
  • 78
    • 84874109849 scopus 로고    scopus 로고
    • Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey
    • Sirota J.C., et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013, 62(3):392-399.
    • (2013) Metabolism , vol.62 , Issue.3 , pp. 392-399
    • Sirota, J.C.1
  • 79
    • 65249087389 scopus 로고    scopus 로고
    • SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle
    • Nakagawa T., et al. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009, 137(3):560-570.
    • (2009) Cell , vol.137 , Issue.3 , pp. 560-570
    • Nakagawa, T.1
  • 80
    • 84891760409 scopus 로고    scopus 로고
    • Sugar, uric acid, and the etiology of diabetes and obesity
    • Johnson R.J., et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013, 62(10):3307-3315.
    • (2013) Diabetes , vol.62 , Issue.10 , pp. 3307-3315
    • Johnson, R.J.1
  • 81
    • 77952680758 scopus 로고    scopus 로고
    • Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study
    • Speliotes E.K., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51(6):1979-1987.
    • (2010) Hepatology , vol.51 , Issue.6 , pp. 1979-1987
    • Speliotes, E.K.1
  • 82
    • 20944450486 scopus 로고    scopus 로고
    • Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
    • Bugianesi E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48(4):634-642.
    • (2005) Diabetologia , vol.48 , Issue.4 , pp. 634-642
    • Bugianesi, E.1
  • 83
    • 84875615668 scopus 로고    scopus 로고
    • Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects
    • Choe Y.G., et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J.Gastroenterol. Hepatol. 2013, 28(4):678-683.
    • (2013) J.Gastroenterol. Hepatol. , vol.28 , Issue.4 , pp. 678-683
    • Choe, Y.G.1
  • 84
    • 80052741269 scopus 로고    scopus 로고
    • Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?
    • Maurantonio M., et al. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch. Med. Res. 2011, 42(5):337-353.
    • (2011) Arch. Med. Res. , vol.42 , Issue.5 , pp. 337-353
    • Maurantonio, M.1
  • 85
    • 83555165946 scopus 로고    scopus 로고
    • Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
    • Armstrong M.J., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J.Hepatol. 2012, 56(1):234-240.
    • (2012) J.Hepatol. , vol.56 , Issue.1 , pp. 234-240
    • Armstrong, M.J.1
  • 86
    • 84857046691 scopus 로고    scopus 로고
    • Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
    • Wong V.W., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61(3):409-415.
    • (2012) Gut , vol.61 , Issue.3 , pp. 409-415
    • Wong, V.W.1
  • 87
    • 84922363507 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
    • Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014, 5(3):211-218.
    • (2014) Frontline Gastroenterol. , vol.5 , Issue.3 , pp. 211-218
    • Dyson, J.K.1    Anstee, Q.M.2    McPherson, S.3
  • 88
    • 84883759656 scopus 로고    scopus 로고
    • Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
    • Verma S., et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013, 33(9):1398-1405.
    • (2013) Liver Int. , vol.33 , Issue.9 , pp. 1398-1405
    • Verma, S.1
  • 89
    • 84898640575 scopus 로고    scopus 로고
    • Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy
    • Karlas T., et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014, 9(3):e91987.
    • (2014) PLoS One , vol.9 , Issue.3 , pp. e91987
    • Karlas, T.1
  • 90
    • 84898827951 scopus 로고    scopus 로고
    • Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations
    • de Ledinghen V., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J.Hepatol. 2014, 60(5):1026-1031.
    • (2014) J.Hepatol. , vol.60 , Issue.5 , pp. 1026-1031
    • de Ledinghen, V.1
  • 91
    • 84890569059 scopus 로고    scopus 로고
    • Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
    • Banerjee R., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J.Hepatol. 2014, 60(1):69-77.
    • (2014) J.Hepatol. , vol.60 , Issue.1 , pp. 69-77
    • Banerjee, R.1
  • 92
    • 84880029856 scopus 로고    scopus 로고
    • MR fat fraction mapping: a simple biomarker for liver steatosis quantification in nonalcoholic fatty liver disease patients
    • Leitao H.S., et al. MR fat fraction mapping: a simple biomarker for liver steatosis quantification in nonalcoholic fatty liver disease patients. Acad. Radiol. 2013, 20(8):957-961.
    • (2013) Acad. Radiol. , vol.20 , Issue.8 , pp. 957-961
    • Leitao, H.S.1
  • 93
    • 77956119396 scopus 로고    scopus 로고
    • Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
    • McPherson S., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59(9):1265-1269.
    • (2010) Gut , vol.59 , Issue.9 , pp. 1265-1269
    • McPherson, S.1
  • 94
    • 79251524594 scopus 로고    scopus 로고
    • Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    • Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011, 33(5):525-540.
    • (2011) Aliment. Pharmacol. Ther. , vol.33 , Issue.5 , pp. 525-540
    • Dowman, J.K.1    Tomlinson, J.W.2    Newsome, P.N.3
  • 95
    • 79959573040 scopus 로고    scopus 로고
    • Endpoints and clinical trial design for nonalcoholic steatohepatitis
    • Sanyal A.J., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
    • (2011) Hepatology , vol.54 , Issue.1 , pp. 344-353
    • Sanyal, A.J.1
  • 97
    • 72449161164 scopus 로고    scopus 로고
    • Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults
    • Shah K., et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009, 17(12):2162-2168.
    • (2009) Obesity (Silver Spring) , vol.17 , Issue.12 , pp. 2162-2168
    • Shah, K.1
  • 98
    • 0025186310 scopus 로고
    • Effect of weight reduction on hepatic abnormalities in overweight patients
    • Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99(5):1408-1413.
    • (1990) Gastroenterology , vol.99 , Issue.5 , pp. 1408-1413
    • Palmer, M.1    Schaffner, F.2
  • 99
    • 2442615980 scopus 로고    scopus 로고
    • Alow-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial
    • Yancy W.S., et al. Alow-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann. Intern Med. 2004, 140(10):769-777.
    • (2004) Ann. Intern Med. , vol.140 , Issue.10 , pp. 769-777
    • Yancy, W.S.1
  • 100
    • 73449116035 scopus 로고    scopus 로고
    • Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
    • Promrat K., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
    • (2010) Hepatology , vol.51 , Issue.1 , pp. 121-129
    • Promrat, K.1
  • 101
    • 84925362378 scopus 로고    scopus 로고
    • Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study
    • (Epub ahead of print)
    • Oh S., et al. Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27544.
    • (2014) Hepatology
    • Oh, S.1
  • 102
    • 33646483917 scopus 로고    scopus 로고
    • Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    • Zelber-Sagi S., et al. Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006, 4(5):639-644.
    • (2006) Clin. Gastroenterol. Hepatol. , vol.4 , Issue.5 , pp. 639-644
    • Zelber-Sagi, S.1
  • 103
    • 0030147221 scopus 로고    scopus 로고
    • Adouble-blind randomized placebo-controlled trial of sibutramine
    • Bray G.A., et al. Adouble-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 1996, 4(3):263-270.
    • (1996) Obes. Res. , vol.4 , Issue.3 , pp. 263-270
    • Bray, G.A.1
  • 104
    • 0034516930 scopus 로고    scopus 로고
    • Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
    • James W.P., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356(9248):2119-2125.
    • (2000) Lancet , vol.356 , Issue.9248 , pp. 2119-2125
    • James, W.P.1
  • 105
    • 79959466159 scopus 로고    scopus 로고
    • Current therapeutic strategies in non-alcoholic fatty liver disease
    • Dowman J.K., et al. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes. Metab. 2011, 13(8):692-702.
    • (2011) Diabetes Obes. Metab. , vol.13 , Issue.8 , pp. 692-702
    • Dowman, J.K.1
  • 106
    • 77956284607 scopus 로고    scopus 로고
    • Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
    • James W.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N.Engl. J. Med. 2010, 363(10):905-917.
    • (2010) N.Engl. J. Med. , vol.363 , Issue.10 , pp. 905-917
    • James, W.P.1
  • 107
    • 33751001942 scopus 로고    scopus 로고
    • Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
    • Scheen A.J., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672.
    • (2006) Lancet , vol.368 , Issue.9548 , pp. 1660-1672
    • Scheen, A.J.1
  • 108
    • 32644441249 scopus 로고    scopus 로고
    • Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
    • Pi-Sunyer F.X., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295(7):761-775.
    • (2006) JAMA , vol.295 , Issue.7 , pp. 761-775
    • Pi-Sunyer, F.X.1
  • 109
    • 17144382751 scopus 로고    scopus 로고
    • Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
    • Van Gaal L.F., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397.
    • (2005) Lancet , vol.365 , Issue.9468 , pp. 1389-1397
    • Van Gaal, L.F.1
  • 110
    • 77956017429 scopus 로고    scopus 로고
    • Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
    • Topol E.J., et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010, 376(9740):517-523.
    • (2010) Lancet , vol.376 , Issue.9740 , pp. 517-523
    • Topol, E.J.1
  • 111
    • 57149101692 scopus 로고    scopus 로고
    • Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis
    • Mummadi R.R., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2008, 6(12):1396-1402.
    • (2008) Clin. Gastroenterol. Hepatol. , vol.6 , Issue.12 , pp. 1396-1402
    • Mummadi, R.R.1
  • 112
    • 0034773404 scopus 로고    scopus 로고
    • Role of AMP-activated protein kinase in mechanism of metformin action
    • Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J.Clin. Invest 2001, 108(8):1167-1174.
    • (2001) J.Clin. Invest , vol.108 , Issue.8 , pp. 1167-1174
    • Zhou, G.1
  • 113
    • 84903273250 scopus 로고    scopus 로고
    • AMPK activation: a therapeutic target for type 2 diabetes?
    • Coughlan K.A., et al. AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes Metab. Syndr. Obes. 2014, 7:241-253.
    • (2014) Diabetes Metab. Syndr. Obes. , vol.7 , pp. 241-253
    • Coughlan, K.A.1
  • 114
    • 84920155380 scopus 로고    scopus 로고
    • Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis
    • Li Y., et al. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. Rep. 2013, 1(1):57-64.
    • (2013) Biomed. Rep. , vol.1 , Issue.1 , pp. 57-64
    • Li, Y.1
  • 115
    • 84862517200 scopus 로고    scopus 로고
    • Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
    • Musso G., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
    • (2012) Diabetologia , vol.55 , Issue.4 , pp. 885-904
    • Musso, G.1
  • 116
    • 1642302410 scopus 로고    scopus 로고
    • Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men
    • Zanchi A., et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J.Clin. Endocrinol. Metab. 2004, 89(3):1140-1145.
    • (2004) J.Clin. Endocrinol. Metab. , vol.89 , Issue.3 , pp. 1140-1145
    • Zanchi, A.1
  • 117
    • 34547700735 scopus 로고    scopus 로고
    • Thiazolidinediones and heart failure: a teleo-analysis
    • Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30(8):2148-2153.
    • (2007) Diabetes Care , vol.30 , Issue.8 , pp. 2148-2153
    • Singh, S.1    Loke, Y.K.2    Furberg, C.D.3
  • 118
    • 33751545838 scopus 로고    scopus 로고
    • Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    • Belfort R., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N.Engl. J. Med. 2006, 355(22):2297-2307.
    • (2006) N.Engl. J. Med. , vol.355 , Issue.22 , pp. 2297-2307
    • Belfort, R.1
  • 119
    • 77951874018 scopus 로고    scopus 로고
    • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
    • Sanyal A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N.Engl. J. Med. 2010, 362(18):1675-1685.
    • (2010) N.Engl. J. Med. , vol.362 , Issue.18 , pp. 1675-1685
    • Sanyal, A.J.1
  • 120
    • 0035462466 scopus 로고    scopus 로고
    • Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men
    • Rask E., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24(9):1640-1645.
    • (2001) Diabetes Care , vol.24 , Issue.9 , pp. 1640-1645
    • Rask, E.1
  • 121
    • 0038121744 scopus 로고    scopus 로고
    • Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    • Vilsboll T., et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114(2-3):115-121.
    • (2003) Regul. Pept. , vol.114 , Issue.2-3 , pp. 115-121
    • Vilsboll, T.1
  • 122
    • 84902661992 scopus 로고    scopus 로고
    • Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease
    • Blaslov K., et al. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(23):7356-7365.
    • (2014) World J. Gastroenterol. , vol.20 , Issue.23 , pp. 7356-7365
    • Blaslov, K.1
  • 123
    • 34249869806 scopus 로고    scopus 로고
    • Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    • Vilsboll T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1608-1610.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1608-1610
    • Vilsboll, T.1
  • 124
    • 0038497464 scopus 로고    scopus 로고
    • Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    • Kolterman O.G., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J.Clin. Endocrinol. Metab. 2003, 88(7):3082-3089.
    • (2003) J.Clin. Endocrinol. Metab. , vol.88 , Issue.7 , pp. 3082-3089
    • Kolterman, O.G.1
  • 125
    • 84902687972 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus
    • Fukuhara T., et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014, 61(130):323-328.
    • (2014) Hepatogastroenterology , vol.61 , Issue.130 , pp. 323-328
    • Fukuhara, T.1
  • 126
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Aschner P., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
    • (2006) Diabetes Care , vol.29 , Issue.12 , pp. 2632-2637
    • Aschner, P.1
  • 127
    • 70349333861 scopus 로고    scopus 로고
    • Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
    • Rosenstock J., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr. Med. Res. Opin. 2009, 25(10):2401-2411.
    • (2009) Curr. Med. Res. Opin. , vol.25 , Issue.10 , pp. 2401-2411
    • Rosenstock, J.1
  • 128
    • 33947156808 scopus 로고    scopus 로고
    • Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    • Buse J.B., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 2007, 29(1):139-153.
    • (2007) Clin. Ther. , vol.29 , Issue.1 , pp. 139-153
    • Buse, J.B.1
  • 129
    • 79955446251 scopus 로고    scopus 로고
    • Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial
    • Lavine J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305(16):1659-1668.
    • (2011) JAMA , vol.305 , Issue.16 , pp. 1659-1668
    • Lavine, J.E.1
  • 130
    • 84862636851 scopus 로고    scopus 로고
    • Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    • Beaton M.D. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can. J. Gastroenterol. 2012, 26(6):353-357.
    • (2012) Can. J. Gastroenterol. , vol.26 , Issue.6 , pp. 353-357
    • Beaton, M.D.1
  • 131
    • 73149092115 scopus 로고    scopus 로고
    • Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
    • Abdelmalek M.F., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
    • (2009) Hepatology , vol.50 , Issue.6 , pp. 1818-1826
    • Abdelmalek, M.F.1
  • 132
    • 77955699301 scopus 로고    scopus 로고
    • High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
    • Leuschner U.F., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(2):472-479.
    • (2010) Hepatology , vol.52 , Issue.2 , pp. 472-479
    • Leuschner, U.F.1
  • 133
    • 1542515099 scopus 로고    scopus 로고
    • Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    • Lindor K.D., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
    • (2004) Hepatology , vol.39 , Issue.3 , pp. 770-778
    • Lindor, K.D.1
  • 134
    • 84900451257 scopus 로고    scopus 로고
    • Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies
    • Zeng T., et al. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur. J. Gastroenterol. Hepatol. 2014, 26(6):646-653.
    • (2014) Eur. J. Gastroenterol. Hepatol. , vol.26 , Issue.6 , pp. 646-653
    • Zeng, T.1
  • 135
    • 84912096773 scopus 로고    scopus 로고
    • Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease
    • Paolella G., et al. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(42):15518-15531.
    • (2014) World J. Gastroenterol. , vol.20 , Issue.42 , pp. 15518-15531
    • Paolella, G.1
  • 136
    • 84886999533 scopus 로고    scopus 로고
    • Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis
    • Ma Y.Y., et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J. Gastroenterol. 2013, 19(40):6911-6918.
    • (2013) World J. Gastroenterol. , vol.19 , Issue.40 , pp. 6911-6918
    • Ma, Y.Y.1
  • 137
    • 84900032263 scopus 로고    scopus 로고
    • Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
    • Alisi A., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39(11):1276-1285.
    • (2014) Aliment. Pharmacol. Ther. , vol.39 , Issue.11 , pp. 1276-1285
    • Alisi, A.1
  • 138
    • 84856763599 scopus 로고    scopus 로고
    • Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis
    • Malaguarnera M., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57(2):545-553.
    • (2012) Dig. Dis. Sci. , vol.57 , Issue.2 , pp. 545-553
    • Malaguarnera, M.1
  • 139
    • 84857802209 scopus 로고    scopus 로고
    • Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis
    • Newsome P.N., et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012, 61(4):484-500.
    • (2012) Gut , vol.61 , Issue.4 , pp. 484-500
    • Newsome, P.N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.